KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Jul 31, 2026. Filed Sep 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jul 31, 2026 · Filed Sep 14, 2026
KMTS$29.55-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended July 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $30,971 | $19,371 |
| Cost of revenue | 13,473 | 10,520 |
| Gross profit | 17,498 | 8,851 |
| Operating expenses: | ||
| Research and development | 6,796 | 4,001 |
| Selling, general and administrative | 48,359 | 33,728 |
| Total operating expenses | 55,155 | 37,729 |
| Loss from operations | (37,657) | (28,878) |
| Other expense (income): | ||
| Interest expense | 1,929 | 1,912 |
| Interest income | (2,125) | (2,167) |
| Other expense (income), net | 272 | (2,830) |
| Loss on extinguishment of debt | 6,304 | — |
| Net loss before provision for income taxes | (44,037) | (25,793) |
| Provision for income taxes | 50 | 33 |
| Net loss attributable to common shareholders, basic and diluted | $(44,087) | $(25,826) |
| Net loss per share attributable to common shareholders, basic and diluted | $(0.75) | $(0.50) |
| Weighted-average shares of common shares outstanding, basic and diluted | 58,566,467 | 51,304,599 |
| Other comprehensive loss: | ||
| Net loss | $(44,087) | $(25,826) |
| Unrealized loss on marketable securities | (253) | — |
| Comprehensive loss | $(44,340) | $(25,826) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.